In the context of intensifying research and laboratory experiments around the world, to reach a better understanding of "Covid-19", and to find a viable strategy to stop it, and in a recent study published by the Journal of the American Society of Microbiology, a multidisciplinary research team suggested that a promising vaccine for a syndrome virus be used. The Respiratory Middle East (MERS), as the approach followed may also work against Covid-19.

A report by the Dubai Future Foundation’s Observatory for the Future said that the approach of the MERS vaccine is limited to the genetic modification of the RNA virus, or the so-called Para influenza 5 (PIV5) virus, which scientists think causes a condition called dogs that causes dogs to cough. It appears harmless to humans by adding a gene that allows infected cells to produce S-protein, a glycoprotein known to be linked to MERS infection.

"We know that people have been infected with the PIV5 virus, and we do not see it harmful to humans," said Paul McCray, a pediatric lung disease specialist and coronavirus expert and professor at the University of Iowa. It does not appear to cause a cytopathic effect. ” Since the MERS virus is not able to reproduce in mice, Macrae developed a mouse-specific model that simulates human infection for vaccine testing, and the mice were genetically modified to show the DB4 protein, a protein that MERS uses as an entry point into human cells. Laboratory tests showed that a single dose of the vaccine, administered through the nose, effectively caused the production of cells infected with S protein, which in turn triggered immune responses against the protein in the animal host.

McCray had previously studied similar strategies, such as a method for treating cystic fibrosis, and said: “We are very interested in using viruses as a way to deliver genes. Finding an effective vaccine against (Covid-19) is a race against time, and people have not been infected with this disease previously, meaning there are many injuries when it reappears, and we have not yet confirmed if the recovered people are acquiring permanent immunity from it or not, so methods must be considered to protect people ».

Experiments in mice

Four weeks after vaccination, the mice were exposed to a strain of MERS virus that was predisposed to cause deadly infection in mice, and the MERS virus was also transmitted to groups of mice that received the PIVV5 vaccine, a vaccine that did not contain the S genes. All mice vaccinated with the modified PIV-5 vaccine survived the infection with the MERS virus, while the mice vaccinated with the PIV-5 vaccine that did not contain the S genes.

- People have not previously contracted this disease, which means there are many injuries upon its re-emergence.

- It has not been confirmed until now if the recovered people have permanent immunity from it or not.